Zydus Lifesciences Shares Rise Despite USFDA Observations
Business
M
Moneycontrol•27-01-2026, 09:30
Zydus Lifesciences Shares Rise Despite USFDA Observations
- •Zydus Lifesciences received three observations from the USFDA following an inspection at its Ankleshwar, Gujarat facility.
- •The inspection at the Unit-2 manufacturing facility took place from January 19 to 23, 2026.
- •The company clarified that there were no data-integrity related observations and committed to addressing the issues promptly.
- •Despite the USFDA observations, Zydus Lifesciences' share price traded higher, up 0.32 percent at Rs 884.80 on BSE.
- •Last week, Zydus launched Tishtha, the world's first biosimilar of Nivolumab, in India.
Why It Matters: Zydus Lifesciences' stock gained despite USFDA observations, as the company plans to address the issues.
✦
More like this
Loading more articles...
